Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Vollenhoven, B.J.
Right arrow Articles by Healy, D.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vollenhoven, B.J.
Right arrow Articles by Healy, D.L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 9, No. 2, pp. 214-219, 1994
© 1994 European Society of Human Reproduction and Embryology

other

Messenger RNA encoding the insulin-like growth factors and their binding proteins, in women with fibroids, pretreated with luteinizing hormone-releasing hormone agonists *

B.J. Vollenhoven1, A.C. Herington2 and D.L. Healy1,3

1Department of Obsterics and Gynaecology, Monash University, Level 5, Monash Medical Centre Clayton Road, Clayton, Victoria 3168 2Department of Clinical Biochemistry, Royal Children's Hospital Flemington Road, Parkville, Victoria 3052, Australia

Correspondence: 3To whom correspondence should be addressed

The primary objective of this study was to suggest a possible mechanism of action of luteinizing hormone-releasing hormone agonist (LHRHa) on fibroids. This was performed by investigating insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1, -2 and -3 mRNA expression in uterine fibroids from women rendered hypo-oestrogenic by LHRHa, using Northern blot analysis. Nine women with fibroids, who were rendered hypo-oestrogenic from at least 4 months pretreatment with LHRHa therapy prior to undergoing myomectomy were investigated. Our results showed that IGF-I, IGF-II, IGFBP-2 and -3 mRNAs were expressed in uterine fibroids, and that IGFBP-1 mRNA or protein was not detected in fibroids. Western ligand blotting showed the presence of IGFBP-2 and -3 proteins, and when compared with a group of women with fibroids not treated with LHRHa (B.J.Vollenhoven et al., 1993, J. Clin. Endocrinol Metab., 76, 1106–1110) we found that there was no difference in the relative abundance for each of the factors between the two groups of women. Therefore, LHRHa act to decrease fibroid size via induction of a hypo-oestrogenic state rather than by changes in the IGFs and their IGFBPs.

Key words: fibroids/IGF/IGFBP/LHRHa

*Presented at The Endocrine Society of Australia meeting, Adelaide, Australia, September 27-30, 1992


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
T. Maruo, N. Ohara, J. Wang, and H. Matsuo
Sex steroidal regulation of uterine leiomyoma growth and apoptosis
Hum. Reprod. Update, May 1, 2004; 10(3): 207 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
K. Englund, B. Lindblom, K. Carlstrom, I. Gustavsson, P. Sjoblom, and A. Blanck
Gene expression and tissue concentrations of IGF-I in human myometrium and fibroids under different hormonal conditions
Mol. Hum. Reprod., October 1, 2000; 6(10): 915 - 920.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.